Synthetic Biologics, Inc. (NYSEAMERICAN:SYN – Get Free Report) shares shot up 1% during trading on Tuesday . The company traded as high as $1.02 and last traded at $1.02. 57,700 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 197,338 shares. The stock had previously closed at $1.01.
Synthetic Biologics Stock Up 1.0 %
The company has a market cap of $16.16 million, a P/E ratio of -0.84 and a beta of 1.38.
About Synthetic Biologics
Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Read More
- Five stocks we like better than Synthetic Biologics
- Best Stocks Under $5.00
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Most Volatile Stocks, What Investors Need to Know
- Hilton Demonstrates Asset Light is Right for Investors
- Insider Buying Explained: What Investors Need to Know
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
